BROSSARD, QUEBEC–(Marketwired – Oct. 18, 2016) – Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today the addition of 2 new pilot projects in North Africa with its strategic pharmaceutical partner.
DIAGNOS will currently have installations in 11 countries worldwide. These new agreements will add an additional 5,000 patients to be screened using the DIAGNOS technology platform. DIAGNOS is using the same approach as all the existing countries, providing turnkey solutions to our clients.
“We are excited to add two more countries to our existing client base bringing the total countries to 11. More and more we, DIAGNOS and our pharmaceutical partner, are working at educating governments around the world of the benefits of our Wellness Program (CARA) and demonstrating the cost savings that can be derived from it. We are continuing to implement our growth strategy with our existing pharmaceutical partner”, said André Larente, DIAGNOS’ President.
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.
This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
(450) 678-8882, ext.: 224